News

AVANT BIO Announces Participation in PL Bioscience’s €7.8 million Series A Financing Round

We are thrilled to announce our latest investment. AVANT BIO has participated in PL Bioscience’s €7.8 ($8.5) million Series A Financing Round along with 3 additional co-investors to their existing investor base. Forward looking PL BioScience is pioneering sustainable, non-animal derived cell culture media. Their Human Platelet Lysate (HPL) technology is derived from donated blood no longer suitable for transfusion. HPL provides a sustainable and effective alternative to animal-derived cell culture media. This technology is pivotal in driving progress in cell therapy development.

In addition to working capital, AVANT BIO will support the PL Bioscience team with decades of cell culture media experience covering key areas including; pricing strategy, supply chain, and global distribution.

We are excited to support PL Biosciences in their next phase of growth as they capitalize on the massive increase in global cell culture media demand.

Read PL Biosciences press release here.

Please follow PL Bioscience to keep up with their latest news: https://www.linkedin.com/company/pl-bioscience/

Visit PL Biosciences to learn more about their technology.